Pilestop450 mg+50 mg

Pilestop is a venotonic (phlebotropic) flavonoid combination used in the management of venous and lymphatic disorders.

Established / Guideline-Supported Uses

• Chronic venous insufficiency (CVI): Pilestop is indicated for the relief of symptoms related to CVI of the lower limbs, such as leg heaviness, pain, nocturnal cramps, and swelling.
• Acute hemorrhoidal attacks: Pilestop is indicated as an adjunct treatment for the symptoms of acute hemorrhoidal disease (pain, bleeding, discomfort), used together with local measures and, when needed, other prescribed treatment.

Adjunct / Supportive Use

• Pilestop may be used as an adjunct to compression therapy and lifestyle measures (leg elevation, exercise, weight control) in chronic venous disease.
• Sometimes used as adjunct supportive therapy in mild lymphedema, although evidence for this use is more limited than for CVI and hemorrhoids.

Pilestop is not a treatment for the underlying structural cause of venous disease (e.g., valve incompetence) or for complicated/thrombosed hemorrhoids, which require separate medical or surgical evaluation.

Each tablet of Micronised Diosmin + Hesperidin contains a micronised purified flavonoid fraction (MPFF), typically standardised to provide diosmin and hesperidin in an approximate 9:1 ratio (commonly diosmin 450 mg and hesperidin 50 mg per 500 mg tablet). Exact strength, ratio, and inactive ingredients vary by manufacturer and formulation, so the product label should always be checked for the precise composition.

Pilestop is an oral, semi-synthetic flavonoid preparation belonging to the venotonic (phlebotropic) drug class. It is manufactured using a micronisation process that reduces particle size, which is intended to improve gastrointestinal absorption compared with non-micronised flavonoid preparations.

Pilestop acts on the venous and lymphatic systems by increasing venous tone, improving lymphatic drainage, and protecting the microcirculation, and it is widely used across many countries, including Bangladesh, for chronic venous insufficiency and hemorrhoidal disease.

Pilestop belongs to the venotonic / vasoprotective (phlebotropic flavonoid) therapeutic class.

Pharmacodynamics: Micronised Diosmin + Hesperidin increases venous tone and vein contractility, reduces venous distensibility and capacitance, and improves venous emptying, which helps reduce venous stasis. It also improves lymphatic drainage by increasing lymphatic contractile activity and the number of functioning lymph capillaries.

At the microcirculatory level, Micronised Diosmin + Hesperidin reduces capillary hyperpermeability and increases capillary resistance. It exerts anti-inflammatory effects by reducing the synthesis and release of inflammatory mediators (such as prostaglandins and thromboxane), and by decreasing leukocyte adhesion, activation, and migration into perivascular tissue, which contributes to its benefit in both venous insufficiency and acute hemorrhoidal episodes.

Pharmacokinetics: The micronised formulation of Micronised Diosmin + Hesperidin is absorbed more rapidly and completely from the gastrointestinal tract than non-micronised flavonoid preparations. Diosmin is largely metabolised to diosmetin and other metabolites, mainly by colonic flora, and elimination occurs predominantly via the faeces, with a smaller portion excreted in urine.

Pilestop tablets should be swallowed whole with a glass of water and taken with meals to help minimise gastrointestinal discomfort. Tablets should not be crushed or chewed unless the product labeling specifically permits it. Doses should be spaced evenly through the day (e.g., morning and evening) and taken at approximately the same times each day for consistent effect.

No major, well-established clinically significant drug interactions have been identified for Pilestop. It is generally considered to have a favourable interaction profile.

As a theoretical precaution, because flavonoids can have mild effects on vascular permeability and platelet/capillary function, caution and physician supervision are advised when Pilestop is used together with anticoagulant or antiplatelet medicines, although no well-established, clinically significant interaction of this kind has been confirmed. Patients should inform their physician of all other medicines, supplements, and herbal products they are taking before starting Pilestop.

Pilestop is generally well tolerated. Reported side effects include:

• Gastrointestinal: diarrhea, dyspepsia, nausea, vomiting (most common; usually mild and transient)
• Neurological: headache, dizziness
• Dermatological: rash, pruritus (uncommon)
• Rare: isolated reports of colitis have been described; discontinue and seek medical advice if severe or persistent abdominal symptoms occur

Patients should seek prompt medical attention for any signs of a hypersensitivity reaction (e.g., facial swelling, difficulty breathing, widespread rash) while taking Pilestop.

Data on the use of Pilestop in human pregnancy are limited. As a general precaution, Pilestop should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use, especially during the first trimester.

It is not well established whether the components of Pilestop pass into breast milk in clinically significant amounts. As a precaution, breastfeeding mothers should consult their physician before using Pilestop, weighing the expected benefit against any potential risk to the infant.

Pilestop is intended for symptomatic relief and is not a substitute for definitive evaluation or treatment of severe or complicated venous disease (e.g., venous ulcers, deep vein thrombosis) or complicated hemorrhoids (e.g., thrombosed or prolapsed hemorrhoids, significant or persistent rectal bleeding). Patients with severe, persistent, or worsening symptoms, or with rectal bleeding, should seek prompt medical evaluation rather than relying on Pilestop alone.

Pilestop does not replace other prescribed measures for chronic venous insufficiency, such as compression stockings, leg elevation, and lifestyle modification.

Use with caution and under medical supervision in patients on anticoagulant or antiplatelet therapy (see Interactions).

Limited data exist on Pilestop overdose. Taking substantially more than the prescribed dose may increase the likelihood of gastrointestinal side effects (such as diarrhea, nausea, or abdominal discomfort). There is no specific antidote for Pilestop overdose.

If an overdose of Pilestop is suspected, seek immediate medical attention or contact a poison control center; treatment should be supportive and symptomatic, as directed by a physician.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: Specific dose adjustment data for Pilestop in renal impairment are limited; use with caution and physician oversight.

Hepatic impairment: Specific dose adjustment data for Pilestop in hepatic impairment are limited; use with caution and physician oversight.

Elderly: No specific dose adjustment is generally required for Pilestop in elderly patients, but they should be monitored as for any patient, particularly if other medical conditions or medicines are present.

Pregnancy and lactation: see Pregnancy and Lactation section above.

Pediatric patients: see Pediatric Uses section below.

For chronic venous insufficiency, Pilestop is often used over the longer term, with the physician periodically reassessing continued need and benefit. For acute hemorrhoidal attacks, Pilestop is typically used as a short course of around one week, following the higher initial dose regimen described in Dosage and Administration. Treatment duration should always follow the prescribing physician's advice.

Micronised Diosmin + Hesperidin belongs to the flavonoid / venotonic drug class, specifically classified as a micronised purified flavonoid fraction (MPFF) with vasoprotective and phlebotropic properties.

Micronised Diosmin + Hesperidin increases venous tone and reduces venous distensibility, improves lymphatic drainage, reduces capillary hyperpermeability, and decreases inflammatory mediator release and leukocyte adhesion in the microcirculation, together improving symptoms of venous insufficiency and hemorrhoidal disease.

The safety and efficacy of Pilestop in children and adolescents have not been well established, and it is not generally recommended for pediatric use outside specific physician direction. Pilestop should only be given to a child if specifically prescribed by a pediatrician who has weighed the potential benefits and risks.